AAV vectors containing rDNA homology display increased chromosomal integration and transgene persistence

Molecular Therapy

Volumn 20, Issue 10, 2012, Pages 1902-1911

  Wang, Zhongya ^a   Lisowski, Leszek ^b   Finegold, Milton J ^a   Nakai, Hiroyuki ^c   Kay, Mark A ^b   Grompe, Markus ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b STANFORD UNIVERSITY   (United States)

^c TEXAS CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 9; FUMARYLACETOACETASE; GENOMIC DNA; PARVOVIRUS VECTOR; RECOMBINANT PARVOVIRUS VECTOR; RIBOSOME DNA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL DIVISION; CHROMOSOMAL INTEGRATION; CONTROLLED STUDY; DNA SEQUENCE; ENZYME DEFICIENCY; GENE CASSETTE; GENE EXPRESSION; GENE LOCUS; GENETIC PARAMETERS; GENETIC SELECTION; GENOME SIZE; HOMOLOGOUS RECOMBINATION; LIVER REGENERATION; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; SEQUENCE HOMOLOGY; SEROTYPE; TRANSGENE; TYROSINEMIA; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRUS DNA CELL DNA INTERACTION;

MUS;

EID: 84866930809     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2012.157     Document Type: Article

References (49)

1. Mingozzi, F and High, KA (2011). Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges. Nat Rev Genet 12: 341-355.
2. Maguire, AM, Simonelli, F, Pierce, EA, Pugh, EN Jr, Mingozzi, F, Bennicelli, J et al. (2008). Safety and effcacy of gene transfer for Leber's congenital amaurosis. N Engl J Med 358: 2240-2248.
3. Simonelli, F, Maguire, AM, Testa, F, Pierce, EA, Mingozzi, F, Bennicelli, JL et al. (2010). Gene therapy for Leber's congenital amaurosis is safe and effective through 1.5 years after vector administration. Mol Ther 18: 643-650.
4. Nathwani, AC, Tuddenham, EG, Rangarajan, S, Rosales, C, McIntosh, J, Linch, DC et al. (2011). Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N Engl J Med 365: 2357-2365.
5. High, KA and Aubourg, P (2011). rAAV human trial experience. Methods Mol Biol 807: 429-457.
6. Nakai, H, Yant, SR, Storm, TA, Fuess, S, Meuse, L and Kay, MA (2001). Extrachromosomal recombinant adeno-associated virus vector genomes are primarily responsible for stable liver transduction in vivo. J Virol 75: 6969-6976.
7. Macdonald, RA (1961). "Lifespan" of liver cells. Autoradio-graphic study using tritiated thymidine in normal, cirrhotic, and partially hepatectomized rats. Arch Intern Med 107: 335-343.
8. Giboney, PT (2005). Mildly elevated liver transaminase levels in the asymptomatic patient. Am Fam Physician 71: 1105-1110.
9. Vandenberghe, LH, Wilson, JM and Gao, G (2009). Tailoring the AAV vector capsid for gene therapy. Gene Ther 16: 311-319.
10. Gao, G, Vandenberghe, LH and Wilson, JM (2005). New recombinant serotypes of AAV vectors. Curr Gene Ther 5: 285-297.
11. Wu, P, Xiao, W, Conlon, T, Hughes, J, Agbandje-McKenna, M, Ferkol, T et al. (2000). Mutational analysis of the adeno-associated virus type 2 (AAV2) capsid gene and construction of AAV2 vectors with altered tropism. J Virol 74: 8635-8647.
12. Wu, Z, Asokan, A, Grieger, JC, Govindasamy, L, Agbandje-McKenna, M and Samulski, RJ (2006). Single amino acid changes can infuence titer, heparin binding, and tissue tropism in different adeno-associated virus serotypes. J Virol 80: 11393-11397.
13. Girod, A, Ried, M, Wobus, C, Lahm, H, Leike, K, Kleinschmidt, J et al. (1999). Genetic capsid modifcations allow effcient re-targeting of adeno-associated virus type 2. Nat Med 5: 1438.
14. Nakai, H, Wu, X, Fuess, S, Storm, TA, Munroe, D, Montini, E et al. (2005). Large-scale molecular characterization of adeno-associated virus vector integration in mouse liver. J Virol 79: 3606-3614.
15. Miller, DG, Trobridge, GD, Petek, LM, Jacobs, MA, Kaul, R and Russell, DW (2005). Large-scale analysis of adeno-associated virus vector integration sites in normal human cells. J Virol 79: 11434-11442.
16. Nakai, H, Montini, E, Fuess, S, Storm, TA, Grompe, M and Kay, MA (2003). AAV serotype 2 vectors preferentially integrate into active genes in mice. Nat Genet 34: 297-302.
17. Johnson, JS and Samulski, RJ (2009). Enhancement of adeno-associated virus infection by mobilizing capsids into and out of the nucleolus. J Virol 83: 2632-2644.
18. Overturf, K, Al-Dhalimy, M, Tanguay, R, Brantly, M, Ou, CN, Finegold, M et al. (1996). Hepatocytes corrected by gene therapy are selected in vivo in a murine model of hereditary tyrosinaemia type I. Nat Genet 12: 266-273.
19. Montini, E, Held, PK, Noll, M, Morcinek, N, Al-Dhalimy, M, Finegold, M et al. (2002). In vivo correction of murine tyrosinemia type I by DNA-mediated transposition. Mol Ther 6: 759-769.
20. Held, PK, Olivares, EC, Aguilar, CP, Finegold, M, Calos, MP and Grompe, M (2005). In vivo correction of murine hereditary tyrosinemia type I by phiC31 integrase-mediated gene delivery. Mol Ther 11: 399-408.
21. Duncan, AW, Hickey, RD, Paulk, NK, Culberson, AJ, Olson, SB, Finegold, MJ et al. (2009). Ploidy reductions in murine fusion-derived hepatocytes. PLoS Genet 5: e1000385.
22. Manno, CS, Pierce, GF, Arruda, VR, Glader, B, Ragni, M, Rasko, JJ et al. (2006). Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat Med 12: 342-347.
23. Fisher, KJ, Jooss, K, Alston, J, Yang, Y, Haecker, SE, High, K et al. (1997). Recombinant adeno-associated virus for muscle directed gene therapy. Nat Med 3: 306-312.
24. Wang, Z, Zhu, T, Qiao, C, Zhou, L, Wang, B, Zhang, J et al. (2005). Adeno-associated virus serotype 8 effciently delivers genes to muscle and heart. Nat Biotechnol 23: 321-328.
25. Eberling, JL, Jagust, WJ, Christine, CW, Starr, P, Larson, P, Bankiewicz, KS et al. (2008). Results from a phase I safety trial of hAADC gene therapy for Parkinson disease. Neurology 70: 1980-1983.
26. Bucher, NLR and Malt, RA (1971). Regeneration of Liver and Kidney. Little Brown: Boston.
27. McIntyre, N and Heathcote, J (1974). The laboratory in the diagnosis and management of viral hepatitis. Clin Gastroenterol 3: 317-336.
28. Ghouri, N, Preiss, D and Sattar, N (2010). Liver enzymes, nonalcoholic fatty liver disease, and incident cardiovascular disease: a narrative review and clinical perspective of prospective data. Hepatology 52: 1156-1161.
29. Larsen, LC and Fuller, SH (1996). Management of acetaminophen toxicity. Am Fam Physician 53: 185-190.
30. Nakai, H, Storm, TA and Kay, MA (2000). Recruitment of single-stranded recombinant adeno-associated virus vector genomes and intermolecular recombination are responsible for stable transduction of liver in vivo. J Virol 74: 9451-9463.
31. Mastrangeli, A, Harvey, BG, Yao, J, Wolff, G, Kovesdi, I, Crystal, RG et al. (1996). "Sero-switch" adenovirus-mediated in vivo gene transfer: circumvention of anti-adenovirus humoral immune defenses against repeat adenovirus vector administration by changing the adenovirus serotype. Hum Gene Ther 7: 79-87.
32. Paulk, NK, Wursthorn, K, Wang, Z, Finegold, MJ, Kay, MA and Grompe, M (2010). Adeno-associated virus gene repair corrects a mouse model of hereditary tyrosinemia in vivo. Hepatology 51: 1200-1208.
33. Miller, DG, Wang, PR, Petek, LM, Hirata, RK, Sands, MS and Russell, DW (2006). Gene targeting in vivo by adeno-associated virus vectors. Nat Biotechnol 24: 1022-1026.
34. Paulk, NK, Loza, LM, Finegold, MJ and Grompe, M (2012). AAV-mediated gene targeting is signifcantly enhanced by transient inhibition of NHEJ or the proteasome in vivo. Hum Gene Ther 23: 658-665.
35. Miller, DG, Petek, LM and Russell, DW (2003). Human gene targeting by adeno-associated virus vectors is enhanced by DNA double-strand breaks. Mol Cell Biol 23: 3550-3557.
36. Li, H, Haurigot, V, Doyon, Y, Li, T, Wong, SY, Bhagwat, AS et al. (2011). In vivo genome editing restores haemostasis in a mouse model of haemophilia. Nature 475: 217-221.
37. Lisowski, L, Lau, A, Wang, Z, Zhang, F, Grompe, M and Kay, MA (2012). Non-random integrating rAAV-rDNA vectors allow for stable transgene expression from rDNA loci. (In this issue).
38. McCarty, DM, Young, SM Jr and Samulski, RJ (2004). Integration of adeno-associated virus (AAV) and recombinant AAV vectors. Annu Rev Genet 38: 819-845.
39. Kalpana, GV (1999). Retroviral vectors for liver-directed gene therapy. Semin Liver Dis 19: 27-37.
40. Overturf, K, al-Dhalimy, M, Ou, CN, Finegold, M, Tanguay, R, Lieber, A et al. (1997). Adenovirus-mediated gene therapy in a mouse model of hereditary tyrosinemia type I. Hum Gene Ther 8: 513-521.
41. Gao, G P, Alvira, MR, Wang, L, Calcedo, R, Johnston, J and Wilson, JM (2002). Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proc Natl Acad Sci USA 99: 11854-11859.
42. Choi, VW, Asokan, A, Haberman, RA and Samulski, RJ (2007). Production of recombinant adeno-associated viral vectors for in vitro and in vivo use. Curr Protoc Mol Biol Chapter 16: Unit 16.25.
43. Grompe, M, al-Dhalimy, M, Finegold, M, Ou, CN, Burlingame, T, Kennaway, NG et al. (1993). Loss of fumarylacetoacetate hydrolase is responsible for the neonatal hepatic dysfunction phenotype of lethal albino mice. Genes Dev 7(12A): 2298-2307.
44. Friedrich, G and Soriano, P (1991). Promoter traps in embryonic stem cells: a genetic screen to identify and mutate developmental genes in mice. Genes Dev 5: 1513-1523.
45. Overturf, K, al-Dhalimy, M, Ou, CN, Finegold, M and Grompe, M (1997). Serial transplantation reveals the stem-cell-like regenerative potential of adult mouse hepatocytes. Am J Pathol 151: 1273-1280.
46. Grompe, M, Caskey, CT and Fenwick, RG (1991). Improved molecular diagnostics for ornithine transcarbamylase defciency. Am J Hum Genet 48: 212-222.
47. Fuller, SA, Takahashi, M and Hurrell, JG (2001). Cloning of hybridoma cell lines by limiting dilution. Curr Protoc Mol Biol Chapter 11: Unit11.8.
48. Brisco, MJ, Latham, S, Bartley, PA and Morley, AA (2010). Incorporation of measurement of DNA integrity into qPCR assays. BioTechniques 49: 893-897.
49. Wang, X, Montini, E, Al-Dhalimy, M, Lagasse, E, Finegold, M and Grompe, M (2002). Kinetics of liver repopulation after bone marrow transplantation. Am J Pathol 161: 565-574.